Nexavar and Sorafenib drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Nexavar (sorafenib tosylate) and Sorafenib (sorafenib). Common drug interactions include dysphagia among females and bone marrow failure among males.

The phase IV clinical study analyzes what interactions people have when they take Nexavar and Sorafenib. It is created by eHealthMe based on reports of 43 people who take the same drugs from the FDA, and is updated regularly.

What is Nexavar?

Nexavar has active ingredients of sorafenib tosylate. It is often used in hepatocellular carcinoma. eHealthMe is studying from 23,250 Nexavar users. Check the latest studies of Nexavar.

What is Sorafenib?

Sorafenib has active ingredients of sorafenib. eHealthMe is studying from 3,201 Sorafenib users. Check the latest studies of Sorafenib.

On Jul, 13, 2026

43 people who take Nexavar and Sorafenib together, and have interactions are studied.

Nexavar and Sorafenib drug interactions.

What are the common drug interactions of Nexavar and Sorafenib, by gender? *:

female:

Dysphagia (a condition in which swallowing is difficult or painful)
Dyspnoea (difficult or laboured respiration)
Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs)
Exposed bone in jaw
Fatigue (feeling of tiredness)
Gait disturbance
Gastritis (inflammation of stomach)
Gastrointestinal disorder (functional problems of gastrointestinal tract)
Gingival pain (gum pain)
Gingival ulceration (ulcer on gums)

male:

Bone marrow failure
Drug intolerance (drug sensitivity)
Metastases to lymph nodes (cancer spreads to lymph node)
Metastases to peritoneum (cancer spreads to peritoneum)
Metastasis (spreadable cancer to other organ from origin)
Decreased appetite
Albumin urine present
Angioedema (rapid swelling of the dermis)
Blood sodium decreased
C-reactive protein increased

What are the common drug interactions of Nexavar and Sorafenib, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Bone marrow failure
Drug intolerance (drug sensitivity)
Lymphadenopathy (disease or enlargement of lymph nodes)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Skin toxicity (skin damage due to toxin/poison)
Acute myeloid leukaemia recurrent (acute cancer in which the bone marrow makes abnormal myeloblast- recurrent)
Myelosuppression (a decrease in the production of blood cells)
Malignant neoplasm progression (cancer tumour came back)
Leukaemia recurrent (repeat cancer of bone marrow or blood cells)

10-19:

n/a

20-29:

n/a

30-39:

Bone marrow failure
Febrile neutropenia (fever with reduced white blood cells)
Neutropenic colitis (inflammation of the cecum, often with involvement of the ascending colon and ileum, a life threatening condition)

40-49:

Malignant neoplasm progression (cancer tumour came back)
Metastases to liver (cancer spreads to liver)
Metastases to lung (cancer spreads to lung)
Metastases to lymph nodes (cancer spreads to lymph node)
Metastases to peritoneum (cancer spreads to peritoneum)
Metastasis (spreadable cancer to other organ from origin)
Neoplasm malignant (cancer tumour)

50-59:

Malignant neoplasm progression (cancer tumour came back)
Nausea (feeling of having an urge to vomit)
Pruritus (severe itching of the skin)
Liver disorder (liver diseases)
Osteomyelitis (infection of bone)
Blood creatinine increased
Hypoglycaemia (deficiency of glucose in the bloodstream)
Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
Vomiting projectile
Dizziness

60+:

Decreased appetite
Malignant neoplasm progression (cancer tumour came back)
Platelet count increased
Red blood cell sedimentation rate increased
Speech disorder
Swollen tongue (swelling of tongue)
Diarrhoea
Fatigue (feeling of tiredness)
Headache (pain in head)
Pneumonia

What are the existing conditions these people have? *

Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 22 people, 51.16%
Renal Cell Carcinoma (a kidney cancer): 6 people, 13.95%
Neoplasm Malignant (cancer tumour): 6 people, 13.95%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 4 people, 9.30%
Lung Neoplasm Malignant (cancer tumour of lung): 4 people, 9.30%
Pain: 3 people, 6.98%
Metastases To Bone (cancer spreads to bone): 3 people, 6.98%

* Approximation only. Some reports may have incomplete information.

Do you take Nexavar and Sorafenib?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously